Eye Health News and Research

Latest Eye Health News and Research

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.

15 Jun 2012

Positive results from Salutaris’ episcleral brachytherapy trial on Wet AMD

Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference.

15 Jun 2012

Cedrus, Tobii to introduce StimTracker

Tobii Technology, the global leader in eye-tracking and interactive gaze technology, announced today that it has partnered with Cedrus, the leading provider of stimuli and response hardware for psychological studies, to introduce the StimTracker for Tobii TX300 Eye Tracker.

15 Jun 2012

Antioxidant rhSOD reduces risk of blindness in extremely low gestational age newborns

Retinopathy of prematurity (ROP) is the second most common cause of childhood blindness in the United States, occurring in half of premature infants born earlier than or at 28 weeks gestational age. The condition is caused by abnormal blood vessel development in the retina of the eye. ROP risk increases with decreasing gestational age.

15 Jun 2012

Invuity closes $25M Series D round of financing

Invuity, a leading developer of state-of-the-art surgical visualization and illumination technology, has raised a $25 million Series D round of financing to expand the development, manufacturing and commercialization of the company's advanced medical devices.

14 Jun 2012

UHCO alumnus donate $5 million to University of Houston

University of Houston College of Optometry (UHCO) alumnus Dr. Doug Barnes and his wife, Molly, have made a $5 million pledge to the University of Houston. The gift will be submitted for state matching funds through the Texas Research Incentive Program.

14 Jun 2012

State roundup: Mass. bill seeking Alzheimer's care standards moves forward

A proposal to create minimum standards for Alzheimer's and dementia care in Massachusetts nursing homes is one step closer to becoming law. The state Senate Tuesday unanimously passed legislation that would require the Massachusetts Department of Public Health, which regulates nursing homes, to establish minimum standards for facilities with dementia care units. The House approved the proposal last month.

14 Jun 2012

Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD

Ophthotech Corporation today announced results from the first clinical trial to show statistically significant superior efficacy over Lucentis (ranibizumab) monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).

14 Jun 2012

Human-derived stem cells can spontaneously form optic cups and retina

Human-derived stem cells can spontaneously form the tissue that develops into the part of the eye that allows us to see, according to a study published by Cell Press in the 5th anniversary issue of the journal Cell Stem Cell.

14 Jun 2012

Investigational Insomnia Medicine from Merck improved patients’ ability to fall and stay asleep according to new phase III Data

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

13 Jun 2012

Telephone intervention improves medication adherence in patients with glaucoma

A telephone intervention trial was associated with improvement in glaucoma medication adherence in both the treatment group and the control group but, when the two groups were compared, interactive telephone calls and tailored print materials did not significantly improve adherence, according to a report of a randomized controlled clinical trial published Online First by Archives of Ophthalmology, a JAMA Network publication.

13 Jun 2012

Researchers hope to use experiences of people with long-term T1D to benefit others

Researchers at Joslin Diabetes Center, supported by JDRF, have completed a study of 158 people who have lived with type 1 diabetes (T1D) for 50 years or more with eye examinations at Joslin over many decades of follow-up, and have concluded that a high proportion of this unique group of patients developed little to no diabetic eye disease over time.

13 Jun 2012

Two video articles describe pre-surgical preparation of corneal tissue

Over 45,000 corneal transplant eye surgeries are performed in the US every year. On June 12, 2012, in an effort to standardize this complex procedure, two video articles describing pre-surgical preparation of corneal tissue were published in JoVE, the Journal of Visualized Experiments.

13 Jun 2012

Viewpoints: Praise for insurers' move to keep consumer protections; Supreme Court's reputation falters

UnitedHealthcare, one of the nation's largest health insurers, announced this week that it would keep some of the popular benefits and consumer protections required by the federal health care law even if the Supreme Court strikes down all or part of it. ... But such voluntary actions are not a substitute for the broader mandatory reforms that will take effect after 2014 under the law.

13 Jun 2012

Genetic variability in the embryo may predispose to cancer in adult life

A study recently published in Nature Genetics provides new evidence that the genetic makeup of the embryo may cause the appearance of tumors in adult life. These results bear out the growing theory that some tumors may have an extremely early origin, tracing to the individual's embryonic development, while offering new clues to understand the genetic causes of certain kinds of cancer, and their prevention and treatment.

13 Jun 2012

Cerebral damage, ROP may increase risk of visual impairment in extremely preterm children

Cerebral damage and retinopathy of prematurity appear to be independently associated with visual impairment among preschool children who were born extremely premature, according to a report published Online First by Archives of Ophthalmology, a JAMA Network publication.

13 Jun 2012

New approach can design antibiotics that kill even 'superbugs'

The world needs new antibiotics to overcome the ever increasing resistance of disease-causing bacteria - but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill even "superbugs" but spare the delicate sensory cells of the inner ear.

12 Jun 2012

RVO advances PresbyLens into final phase of trial for treatment of presbyopia

ReVision Optics, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announces the advancement of its proprietary product PresbyLens into the final phase of its U.S. clinical trial under an Investigational Device Exemption

12 Jun 2012

Lexicon presents six posters on LX4211 at ADA meeting

Lexicon Pharmaceuticals, Inc. will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012.

10 Jun 2012

UF Proton Therapy Institute successfully treats first eye cancer patient

The fixed beam room, or eyeline, at the University of Florida Proton Therapy Institute is up and running and radiation oncologist Robert Malyapa, M.D., Ph.D. completed treating the facility's first eye cancer patient this week.

10 Jun 2012

Eye Health News and Research

Latest Eye Health News and Research

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Positive results from Salutaris’ episcleral brachytherapy trial on Wet AMD

Cedrus, Tobii to introduce StimTracker

Antioxidant rhSOD reduces risk of blindness in extremely low gestational age newborns

Invuity closes $25M Series D round of financing

UHCO alumnus donate $5 million to University of Houston

State roundup: Mass. bill seeking Alzheimer's care standards moves forward

Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD

Human-derived stem cells can spontaneously form optic cups and retina

Investigational Insomnia Medicine from Merck improved patients’ ability to fall and stay asleep according to new phase III Data

Telephone intervention improves medication adherence in patients with glaucoma

Researchers hope to use experiences of people with long-term T1D to benefit others

Two video articles describe pre-surgical preparation of corneal tissue

Viewpoints: Praise for insurers' move to keep consumer protections; Supreme Court's reputation falters

Genetic variability in the embryo may predispose to cancer in adult life

Cerebral damage, ROP may increase risk of visual impairment in extremely preterm children

New approach can design antibiotics that kill even 'superbugs'

RVO advances PresbyLens into final phase of trial for treatment of presbyopia

Lexicon presents six posters on LX4211 at ADA meeting

UF Proton Therapy Institute successfully treats first eye cancer patient

Genetics & Genomics - Second Edition eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in